findmyKOL
Clinical trialNCT02973360UnknownPhase 2Interventional

Dose-Finding Study of SC411 in Children With Sickle Cell Disease

SponsorMicelle BioPharma IncEnrollment68Sickle Cell Disease
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of SC411 in children with sickle cell disease (SCD). The primary objective of the study is to evaluate the safety and tolerability of three different doses of SC411 compared to a placebo. All patients will undergo eight weeks of oral study treatment and a four-week safety follow-up period. Patients will be randomized to one of three dose levels of SC411 or placebo.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Children'S of Alabama - University of Alabama

    Birmingham, Alabama, United States

  • Ucsf Benioff Children'S Hospital Oakland

    Oakland, California, United States

  • University of Florida Health at Shands

    Gainesville, Florida, United States

  • Batchelor Children'S Research Institute - University of Miami

    Miami, Florida, United States

  • Children'S Healthcare of Atlanta - Emory University

    Atlanta, Georgia, United States

  • Boston Children'S Hospital

    Boston, Massachusetts, United States

  • Children'S Hospital of Michigan

    Detroit, Michigan, United States

  • University of Mississippi Medical Center

    Jackson, Mississippi, United States

  • East Carolina University

    Greenville, North Carolina, United States

  • Medical University of South Carolina

    Charleston, South Carolina, United States

  • Texas Children'S Hospital - Baylor College of Medicine

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DocosahexaenoatePlacebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Mar 2017
Primary completion
26 Sept 2017
Completion
2 Jan 2022
Last update posted
31 Jan 2019
Registered enrollment
68
Registry id
NCT02973360
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.